Alzheimer's disease

SciNeuro Pharmaceuticals Announces a License and Option Agreement with GSK to Progress Development of Novel Therapies for CNS Diseases
BioSpace
Wed, 06/1/22 - 09:46 am
SciNeuro
CNS
GSK
Alzheimer's disease
Medicare premiums to remain unchanged after Aduhelm price cut spurs review
BioPharma Dive
Tue, 05/31/22 - 11:56 pm
Medicare
Medicare Part B
Biogen
Aduhelm
HHS
Alzheimer's disease
Cumulus puts its digital biomarkers for CNS diseases to the test
Pharmaforum
Thu, 05/26/22 - 10:09 am
Cumulus Neuroscience
clinical trials
biomarkers
diagnostics
Alzheimer's disease
Survey puts spotlight on US neurologists’ response to CMS Alzheimer drugs decision
Biopharma Reporter
Mon, 05/16/22 - 10:48 am
Biogen
Aduhelm
monoclonal antibodies
CMS
Alzheimer's disease
neurologists
Simulation model shows potential clinical value of Eisai drug for patients with early AD
Biopharma Reporter
Mon, 05/9/22 - 10:15 am
Eisai
Alzheimer's disease
lecanemab
New Quest Alzheimer’s blood test can help clinical trial sponsors identify patients easily
MedCity News
Thu, 05/5/22 - 10:36 am
diagnostics
Medtech
Quest Diagnostics
Alzheimer's disease
Biogen shoves Aduhelm to the side. It's time for lecanemab
Fierce Biotech
Wed, 05/4/22 - 10:33 am
Biogen
Aduhelm
lecanemab
Eisai
Alzheimer's disease
Is Biogen Planning to Appeal CMS Aduhelm Reimbursement Decision?
BioSpace
Mon, 05/2/22 - 06:08 pm
Biogen
CMS
Alzheimer's disease
Aduhelm
Things Just Got Worse for Biogen
Motley Fool
Tue, 04/26/22 - 10:18 am
Biogen
Aduhelm
Alzheimer's disease
Europe
Vumerity
multiple sclerosis
digital health
Does Eli Lilly's Future Depend on its Alzheimer's Drug?
Motley Fool
Sat, 04/23/22 - 04:02 pm
Eli Lilly
Alzheimer's disease
donanemab
Biogen pulls European application for Aduhelm in another setback for the Alzheimer's drug
BioPharma Dive
Fri, 04/22/22 - 10:49 am
Biogen
Aduhelm
Europe
Alzheimer's disease
Cassava Faces Renewed Speculation Over Experimental Alzheimer’s Drug
BioSpace
Tue, 04/19/22 - 11:44 pm
Cassava Sciences
Alzheimer's disease
simufilam
A potential target for Alzheimer's treatment? Researchers unearth new immune response pathway
Endpoints
Mon, 04/18/22 - 11:53 pm
drug development
R&D
Alzheimer's disease
The next battle in the never-ending war over Aduhelm
Stat
Fri, 04/15/22 - 01:50 pm
Biogen
Aduhelm
Medicare
CMS
Eli Lilly
Alzheimer's disease
Alzheimer's biotech Alzheon nets $50M Series D
Endpoints
Thu, 04/14/22 - 10:53 am
Alzheon
funding
Alzheimer's disease
ALZ-801
How CMS independence is at the forefront of its Alzheimer's drug coverage decision
Endpoints
Mon, 04/11/22 - 10:34 am
CMS
Medicare
Biogen
Aduhelm
Alzheimer's disease
With Aduhelm slapped down by CMS, what's next for Biogen?
Fierce Pharma
Fri, 04/8/22 - 10:29 am
Biogen
Aduhelm
Medicare
Alzheimer's disease
CMS finalizes restrictions on Biogen's Alzheimer's drug coverage, will only fund use in clinical trials
Endpoints
Thu, 04/7/22 - 06:13 pm
Biogen
Aduhelm
CMS
Alzheimer's disease
clinical trials
Medicare
20 years in, Genentech persists and perseveres in Alzheimer's with gantenerumab
Fierce Biotech
Wed, 04/6/22 - 07:44 pm
Roche
Genentech
Alzheimer's disease
gantenerumab
'About as true as saying the earth is flat': Alzheimer's expert picks apart Biogen's Aduhelm manuscript
Endpoints
Mon, 04/4/22 - 11:22 pm
Biogen
Aduhelm
Alzheimer's disease

Pages